| Literature DB >> 28009290 |
Yanxia Guo1, Kenzie D MacIsaac2, Yi Chen1, Richard J Miller2, Renu Jain1, Barbara Joyce-Shaikh1, Heidi Ferguson2, I-Ming Wang3, Razvan Cristescu1, John Mudgett4, Laura Engstrom2, Kyle J Piers2, Gretchen A Baltus2, Kenneth Barr2, Hongjun Zhang2, Huseyin Mehmet2, Laxminarayan G Hegde2, Xiao Hu5, Laura L Carter5, Thomas D Aicher5, Gary Glick5, Dennis Zaller2, Abbas Hawwari6, Craig C Correll2, Dallas C Jones2, Daniel J Cua7.
Abstract
Recent studies have elucidated the molecular mechanism of RORγT transcriptional regulation of Th17 differentiation and function. RORγT was initially identified as a transcription factor required for thymopoiesis by maintaining survival of CD4+CD8+ (DP) thymocytes. While RORγ antagonists are currently being developed to treat autoimmunity, it remains unclear how RORγT inhibition may impact thymocyte development. In this study, we show that in addition to regulating DP thymocytes survival, RORγT also controls genes that regulate thymocyte migration, proliferation, and T cell receptor (TCR)α selection. Strikingly, pharmacological inhibition of RORγ skews TCRα gene rearrangement, limits T cell repertoire diversity, and inhibits development of autoimmune encephalomyelitis. Thus, targeting RORγT not only inhibits Th17 cell development and function but also fundamentally alters thymic-emigrant recognition of self and foreign antigens. The analysis of RORγ inhibitors has allowed us to gain a broader perspective of the diverse function of RORγT and its impact on T cell biology.Entities:
Keywords: RORγT; T cell repertoire; autoimmunity; experimental autoimmune encephalomyelitis; experimental psoriasis; small-molecule antagonist; thymopoiesis
Mesh:
Substances:
Year: 2016 PMID: 28009290 DOI: 10.1016/j.celrep.2016.11.073
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423